Facebook
Twitter
LinkedIn
Forward
An Update on the Unmet Needs in the Care of Patients With Ulcerative Colitis and Emerging Treatment (Archived CME/CE Monograph)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
Ulcerative colitis (UC) is a chronic inflammatory condition characterized by abdominal cramping, bloody stools, tenesmus, and urgency. Manifesting most often in adolescence and early adulthood, UC exhibits considerable clinical heterogeneity and frequently detracts from patient-related quality of life. Although the quantity and quality of options to treat UC has risen over time, opportunities remain to optimize care for those diagnosed with this highly disruptive disease. The desired results of this activity are to improve the care of patients living with UC. This activity will also be available through CMEZone and Gastroenterology & Endoscopy News.
Review Date: October 31, 2022
Target Audience
This educational activity is intended for gastroenterologists, gastroenterology physician assistants, and nurse practitioners involved in the care of patients with ulcerative colitis.
Learning Objectives
After completing this activity, participants will be better able to:
- Discuss the importance of considering the effect of ulcerative colitis on patients’ quality of life
- Integrate disease activity and quality of life assessments into routine management of ulcerative colitis
- Describe the limitations associated with current treatments for moderate to severe ulcerative colitis
- Review current guidelines for treatment escalation as part of the management of moderate to severe ulcerative colitis
- Summarize the benefits and limitations of S1P modulators for patients with moderate to severe ulcerative colitis
Faculty
William J. Sandborn, MD (Chair)
Professor of Medicine
University of California, San Diego
La Jolla, California
Laurent Peyrin-Biroulet, MD, PhD
Head of Team 2
INSERM U1256 NGERE
University of Lorraine
Professor of Gastroenterology
Nancy University Hospital
Vandoeuvre-lès-Nancy, France
Bruce E. Sands, MD, MS
Chief, Division of Gastroenterology
Dr Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
Séverine Vermeire, MD, PhD
Professor of Medicine
Catholic University
Leuven, Belgium
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Faculty
Laurent Peyrin-Biroulet, MD, PhD, is a consultant for AbbVie Inc, Allergan, Alma Bio Therapeutics, Amgen Inc, Applied Molecular Transport Inc, Arena Pharmaceuticals, Inc, Biogen Idec, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion Inc, Eli Lilly and Company, Enterome, Enthera, F. Hoffmann-La Roche Ltd, Ferring BV, Fresenius Kabi USA, Genentech, Inc, Gilead, Hikma Pharmaceuticals PLC, InDex Pharmaceuticals Holding AB, Janssen Pharmaceutica NV, Merck Sharp & Dohme Corp, Mylan NV, Nestlé, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pfizer Inc, Pharmacosmos A/S, Samsung Bioepis, Sandoz International GmbH, Sterna Biologicals, Sublimity Therapeutics, Takeda Pharmaceutical Company Limited, Tillots Pharma AG, and Vifor Pharma, Inc; and is a contracted researcher for AbbVie Inc, Merck Sharp & Dohme Corp, and Takeda Pharmaceutical Company Limited.
William J. Sandborn, MD, is a consultant for AbbVie Inc, Abivax, Admirx Inc, Alfasigma USA, Inc, Alimentiv, Alivio Therapeutics, Allakos Inc, Amgen Inc, Applied Molecular Transport Inc, Arena Pharmaceuticals, Inc, Bausch Health Companies Inc, BeiGene, Bellatrix Pharmaceuticals, Inc, Boehringer Ingelheim International GmbH, Boston Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion Inc, Celularity Inc, Cosmo Pharmaceuticals NV, Eli Lilly and Company, Equillium, Inc, Escalier Biosciences BV, F. Hoffmann-La Roche Ltd, Forbion, Genentech, Inc, Gilead, Glenmark, Gossamer Bio, Immunic, Inc, InDex Pharmaceuticals Holding AB, Intact Therapeutics, Inc, Janssen Pharmaceuticals, Inc, Kyverna Therapeutics, Inc, Landos Biopharma, Oppilan Pharma Ltd, Otsuka America Pharmaceutical, Inc, Pandion Therapeutics, Inc, Pfizer Inc, Progenity, Inc, Prometheus Biosciences, Protagonist Therapeutics, Inc, Provention Bio, Inc, Reistone Biopharma, Salix Pharmaceuticals, Seres Therapeutics, Shanghai Pharma Biotherapeutics USA Inc, Shire, Shoreline Biosciences, Sublimity Therapeutics, Surrozen, Takeda Pharmaceuticals USA, Inc, Theravance Biopharma, Inc, Thetis Pharmaceuticals LLC, Tillotts Pharma AG, UCB SA, Vedanta Biosciences, Inc, Ventyx Biosciences, Inc, Vimalan Biosciences, Inc, Vivelix Pharmaceuticals, Ltd, Vivreon Biosciences, LLC, and Zealand Pharma; is a contracted researcher for AbbVie Inc, Abivax, Arena Pharmaceuticals, Inc, Boehringer Ingelheim GmbH, Celgene Corporation, Eli Lilly and Company, Genentech, Inc, Gilead, GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Pfizer Inc, Prometheus Biosciences, Seres Therapeutics, Shire, Takeda Pharmaceuticals USA, Inc, and Theravance Biopharma, Inc; and has ownership interest (stock or stock options) in Allakos Inc, BeiGene, Gossamer Bio, Oppilan Pharma Ltd, Progenity, Inc, Prometheus Biosciences, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Inc, and Vivreon Biosciences, LLC.
Bruce E. Sands, MD, MS, is a consultant for Abivax, Arena Pharmaceuticals, Inc, Bacainn Therapeutics, Boehringer Ingelheim International GmbH, Boston Pharmaceuticals, Celltrion Inc, Ironwood Pharmaceuticals, Inc, Kallyope, Protagonist Therapeutics, Inc, Takeda Pharmaceuticals USA, Inc, Takeda (China) Holdings Co, Ltd, Takeda Distribuidora Ltda, Target RWE, US WorldMeds, LLC, and Viela Bio; and is an advisory board member of Eli Lilly and Company, Genentech, Inc, Gilead, GlaxoSmithKline, InDex Pharmaceuticals Holding AB, Inotrem SA, Janssen Pharmaceuticals, Inc, Pfizer Inc, Prometheus Biosciences, and Surrozen.
Séverine Vermeire, MD, PhD, is a consultant for AbbVie Inc, Arena Pharmaceuticals, Inc, Avaxia Biologics, Boehringer Ingelheim International GmbH, Celgene Corporation, Circle33, LLC, Dr. Falk Pharma GmbH, F. Hoffmann-La Roche Ltd, Ferring BV, Galapagos NV, Genentech, Inc, Gilead, Janssen Pharmaceutica NV, Merck Sharp & Dohme Corp, Mundipharma GmbH, Pfizer Inc, ProDigest, Progenity, Prometheus Biosciences, Second Genome, Shire, Takeda Pharmaceutical Company Limited, Theravance Biopharma, Inc, and Tillots Pharma AG; is on the speakers bureau for AbbVie Inc, Dr. Falk Pharma GmbH, F. Hoffmann-La Roche Ltd, Ferring BV, Galapagos NV, Genentech, Inc, Gilead, Janssen Global Services, LLC, Mundipharma GmbH, MSD (Merck Sharp & Dohme Corp), Pfizer Inc, Shire, Takeda Pharmaceutical Company Limited, and Tillots Pharma AG; and is a contracted researcher for AbbVie Inc, Galapagos NV, Johnson & Johnson Vision Care, Inc, Pfizer Inc, and Takeda Pharmaceutical Company Limited.
Peer Reviewer Disclosure
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
For Physicians:
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For Nurses:
Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Credit
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Arena Pharmaceuticals, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Arena Pharmaceuticals, Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 242